Warnings Up As FDA Trims Its List Of Uninspected OTC Drug Manufacturers
Executive Summary
Hundreds of foreign OTC drug firms marketing products in US had not been inspected for GMP compliance before FDA Safety and Innovation Act of 2012 pointed agency toward crossing those facilities off its list. Of the foreign OTC facilities inspected between June 2016 and January 2018, 25% received "official action indicated" inspection results, prompting warning letters and import alerts.
You may also be interested in...
FDA’s Record-Number GMP Warnings In FY 2019 Included First Of A Kind
Total GMP warnings in FY19 was 98, more than half to US firms. Warning to Dollar Tree “should serve as a reminder that although distributors may not be subject to CGMP requirement themselves, they are responsible for ensuring the drugs they distribute into interstate commerce are not adulterated,” says CDER compliance chief Donald Ashley.
Adulterated OTCs Reach Dollar Tree, Third-Party Test Lab Missed Problems
Warning links retailers to multiple manufacturers inspected after FDASIA in 2012 pointed FDA toward inspecting all ex-US firms supplying products available in US but that had yet to be inspected for compliance. Manufacturers also were placed on import alerts to prevent their products, including cosmetics as well as drugs, from reaching US.
US FDA Warns Second Ningbo, China, OTC Firm In Two Weeks On Violations
Hand sanitizer, shampoo, acne scrub, other products available in US under brands including AuraFresh, Halsa, Spa Mystique deemed adulterated due to GMP problems found during an inspection at Pulisi Daily's facility in city in Zhejiang Province.